Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–719 of 719 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Colitis Clear all
Recruiting Phase 1 Interventional

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

NCT03819296
View directory record Official record
Conditions
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Pathologic Stage 0 Cutaneous Melanoma AJCC v8, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Best Practice, Biospecimen Collection, Endoscopic Procedure, Fecal Microbiota Transplantation, Infliximab, Laboratory Biomarker Analysis, Prednisone, Vedolizumab
Other · Procedure · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 6:05 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis

NCT00583531
View directory record Official record
Conditions
Pouchitis
Interventions
AST-120
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 23, 2026, 6:05 PM EDT
Withdrawn No phase listed Observational

Eosinophilic Gastrointestinal Disorders Patient Registry

NCT01779154
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Enteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 23, 2026, 6:05 PM EDT
Terminated Phase 4 Interventional Results available

Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

NCT03591770
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
SHINGRIX
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 23, 2026, 6:05 PM EDT
Recruiting Phase 3 Interventional

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07577856
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
JNJ-78934804, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
24
States / cities
Anaheim, California • Chula Vista, California • Los Alamitos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 6:05 PM EDT
Enrolling by invitation Not applicable Interventional

Thermal Measurements of the Gut With a Colonoscope Compatible Thermal Probe

NCT07352995
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Feasibility of using a thermal probe to measure temperature rise in colonic mucosa
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 23, 2026, 6:05 PM EDT
Completed No phase listed Observational

Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort

NCT02897271
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Little Rock, Arkansas • Denver, Colorado • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 23, 2026, 6:05 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis

NCT00336492
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
infliximab
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 23, 2026, 6:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis

NCT00151892
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SPD476, Asacol
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Bristol, Connecticut • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 23, 2026, 6:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT06260163
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Guselkumab Subcutaneous, Guselkumab Intravenous
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Oakland, California • Indianapolis, Indiana • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 6:05 PM EDT
Terminated Not applicable Interventional

Metabolic Response to Infliximab in Pediatric Ulcerative Colitis

NCT00586807
View directory record Official record
Conditions
Ulcerative Colitis, Protein Metabolism, Energy Expenditure
Interventions
Stable amino acid isotopes
Other
Lead sponsor
Indiana University
Other
Eligibility
6 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 30, 2009 · Synced Oct 23, 2026, 6:05 PM EDT
Completed Not applicable Interventional

Random Comparison of LigaSure and Disposable Staples for Laparoscopic Surgery

NCT00487409
View directory record Official record
Conditions
Colonic Diseases, Rectal Diseases
Interventions
Bipolar electrosurgical generator and instruments, Disposable stapling instruments
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 23, 2026, 6:05 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis

NCT03893565
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
GSK2831781 - Double Blind Phase, Placebo, GSK2831781 - Open Label phase
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Northridge, California • Rialto, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 23, 2026, 6:05 PM EDT
Completed Phase 1 Interventional Results available

Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases

NCT01560819
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD)
Interventions
Gut Microbial Transplantation
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
7 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 23, 2026, 6:05 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT04677179
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Litchfield Park, Arizona • Kissimmee, Florida • Pensacola, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 23, 2026, 6:05 PM EDT
Completed No phase listed Observational

A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients

NCT02497417
View directory record Official record
Conditions
Gastroenteritis, Infectious Colitis
Interventions
Not listed
Lead sponsor
Luminex Corporation
Industry
Eligibility
Not listed
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Tampa, Florida • Indianapolis, Indiana • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 23, 2026, 6:05 PM EDT
Active, not recruiting No phase listed Observational

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

NCT03251118
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
2 Years and older
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
37
States / cities
Lancaster, California • Mission Hills, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 23, 2026, 6:05 PM EDT
Withdrawn Not applicable Interventional

Vitamin D Treatment in Ulcerative Colitis

NCT01640496
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Vitamin D3, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 23, 2026, 6:05 PM EDT
Completed Phase 2 Interventional

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06049017
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
32
States / cities
Anaheim, California • Newport Beach, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 6:05 PM EDT
Completed Phase 1 Interventional

Evaluation of DHA for the Treatment of PSC

NCT00325013
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Colitis
Interventions
Docosahexaenoic Acid (DHA)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 23, 2026, 6:05 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

NCT05119140
View directory record Official record
Conditions
Ulcerative Colitis (Disorder)
Interventions
Hydroxychloroquine, Mesalamine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 23, 2026, 6:05 PM EDT
Recruiting No phase listed Observational

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

NCT06398626
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Mesa, Arizona • La Jolla, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 6:05 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis

NCT00572585
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AEB071, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Mobile, Alabama • Mesa, Arizona • Topeka, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 23, 2026, 6:05 PM EDT